Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases.
- Published in:
- BioDrugs, 2024, v. 38, n. 2, p. 177, doi. 10.1007/s40259-024-00644-7
- By:
- Publication type:
- Article
Works matching IS 11738804 AND DT 2024 AND VI 38 AND IP 2
Results: 11
1
2
Cardiovascular Adverse Drug Reactions of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies for Migraine Prevention: An Analysis from the European Spontaneous Adverse Event Reporting System.
- Published in:
- BioDrugs, 2024, v. 38, n. 2, p. 275, doi. 10.1007/s40259-024-00651-8
- By:
- Publication type:
- Article
3
Nano–Bio Interactions: Exploring the Biological Behavior and the Fate of Lipid-Based Gene Delivery Systems.
- Published in:
- BioDrugs, 2024, v. 38, n. 2, p. 259, doi. 10.1007/s40259-024-00647-4
- By:
- Publication type:
- Article
4
Recombinant Antibody Fragments for Immunotherapy of Parkinson's Disease.
- Published in:
- BioDrugs, 2024, v. 38, n. 2, p. 249, doi. 10.1007/s40259-024-00646-5
- By:
- Publication type:
- Article
5
Correction to: Is the Availability of Biosimilar Adalimumab Associated with Budget Saving? A Difference-in-Difference Analysis of 14 Countries.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
6
Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors?
- Published in:
- BioDrugs, 2024, v. 38, n. 2, p. 171, doi. 10.1007/s40259-024-00643-8
- By:
- Publication type:
- Article
7
Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies.
- Published in:
- BioDrugs, 2024, v. 38, n. 2, p. 205, doi. 10.1007/s40259-023-00641-2
- By:
- Publication type:
- Article
8
Unveiling the Biosimilar Paradox of Oncologists' Perceptions and Hesitations in South Korea: A Web-Based Survey Study.
- Published in:
- BioDrugs, 2024, v. 38, n. 2, p. 301, doi. 10.1007/s40259-023-00640-3
- By:
- Publication type:
- Article
9
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N: A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers.
- Published in:
- BioDrugs, 2024, v. 38, n. 2, p. 313, doi. 10.1007/s40259-023-00637-y
- By:
- Publication type:
- Article
10
Molecular Engineering of Interleukin-2 for Enhanced Therapeutic Activity in Autoimmune Diseases.
- Published in:
- BioDrugs, 2024, v. 38, n. 2, p. 227, doi. 10.1007/s40259-023-00635-0
- By:
- Publication type:
- Article
11
Safety, Tolerability, and Preliminary Efficacy of Serplulimab, a Novel Anti-PD-1 Antibody, in Patients with Metastatic or Recurrent Solid Tumors: A Phase I Study.
- Published in:
- BioDrugs, 2024, v. 38, n. 2, p. 287, doi. 10.1007/s40259-023-00639-w
- By:
- Publication type:
- Article